



# **Charlotte Taylor, Umesh Chauhan and Shalom J Srirangam**

**Contact: charley.19968@hotmail.co.uk** 

## INTRODUCTION

Prostate Cancer (PCa) is the most common cancer in males in the UK. In 2018, **47,700 men were diagnosed** with PCa and around **11,600 men died** as a result of PCa in the UK<sup>1</sup>.

There appears to a pronounced degree of racial variation within prostate cancer. Previous research on ethnic variation within PCa incidences has been limited in accuracy due to medical disparities and incomplete cancer registries, but available UK cancer statistics also show a higher risk of prostate cancer in men from an African/ Caribbean background compared to their Caucasian counterparts. Furthermore PCa appears less common in men of South Asian background (Indian/Pakistani/Bangladeshi/ Sri Lankan) living in the UK although the reason for this has not been studied in any detail.

Aye at Diagnosis (years)									
	Median	Mode	Average	SD	Highest	Lowest			
South Asian Group	68	69	66.6	8.8	88	40			
Caucasian Group	69	69	69.0	9.2	96	36			
DCA at Diagnosis (ng/ml)									

And at Diagnosis (vears)

#### **First Line Treatment Choices**



**East Lancashire** has a sizeable South Asian population and, since 2009, 113 men have been diagnosed with prostate cancer at East Lancashire Hospital NHS Trust (ELHT). This unique group has not been studied and little is known about the patterns and challenges of prostate cancer diagnosis and **management** in South Asian men.

The **aim** of this project was to **scrutinise PCa characteristics** in this unique group of South Asian patients and where possible compare these parameters with Caucasian patients with PCa at

#### **METHOD**

We undertook a **retrospective patient record analysis** of the notes of 113 South Asian men with PCa diagnosed or **managed** in **ELHT** between 2009–2019 (South Asian group).

Data was obtained from paper based notes, electronic records and multidisciplinary team (MDT) discussion data from the Somerset Cancer Register.

Key demographic and clinical parameters were recorded including; age at presentation, biochemical markers, nature of symptoms, role of screening, communication issues, grade and **stage** of disease, trends in **treatment** choices, the presence of other cancer and non-cancer co-morbidities.

#### **PSA at Diagnosis (ng/mi)**

	Median	Mode	Average	SD	Highest	Lowest				
South Asian Group	8.7	10.4	51.70	283.8	2930	0.10				
Caucasian Group	11.8	7.2	123.08	700.2	16717	0.03				
Gleason Scores										







## **Communication Issues Within South Asian Group**



## RESULTS

- The rate of PCA diagnosis has been steadily increasing in both groups.
- Age at diagnosis for both groups was very **similar**.
- **PSA levels** at presentation were **generally lower** for **South Asians** compared to Caucasian patients.
- Histological Gleason scores at diagnosis were generally lower for **South Asians** patients with a score of 3+3 category being the most predominant score.

The **Caucasian group** comprised **2872** patients diagnosed with PCa at ELHT during the same 10 year period. Collated data for this group was obtained directly from the Somerset Cancer Register.

In the South Asian study group (n=113), the **median age** at the time of diagnosis was **68** years (40-88). The **median follow up period** (time of diagnosis to the study/death) was **54** months (2-240).

The study was registered as a URIP project with UCLan and with the Audit department at ELHT. No ethics committee approval was necessary.

**Total Recorded PCa Incidences at ELTH in Caucasian and South** Asian Men (2009–2019)



**Caucasian Group** 

41-50

51-60

61-70

71-80

#### **Associated Co-Morbidities with South Group**

Out patient (trans-rectal

biopsies)



- In almost a **third of patients**, the referring physician had **not** suspected a possible diagnosis of PCa.
- **Communication issues** were **frequently encountered** with South Asian patients with a large proportion being reliant on family members or interpreters to help with the consultation, potentially making detailed discussions inefficient.
- With regards to treatment choices, **South Asian patients** were more likely to **not require active interventional treatment**; more likely to undergo radical radiotherapy rather than surgery; and less likely to go on hormonal manipulation compared to their Caucasian counterparts.
- **81%** of the South Asian patients had demonstrated no evidence of disease progression and only 8 (7%) patients had **died** as a result of PCa.

### DISCUSSION

This preliminary study provides interesting insights into the issues facing PCa diagnosis and management in South Asian men in East Lancashire. There is evidence of **differences** between this sub-group and Caucasian patients with PCa, though this study cannot yet provide explanations for these patterns.

The role of ethnicity in PCa development is complex and poorly understood. It is clear that more prospective, multi-modality research is needed to scope the entire PCa pathway for South Asian men from referral in primary care to diagnosis and management in secondary care, to focus on areas including:



#### **References:**

L. Cancer Research UK, https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ prostate-cancer#heading-One , Accessed: September 2019.



**PSA Progression Status for South Asian Patients After First Line Treatment** 



- The **impact** of public and median **PCa** campaigns on the South Asian population in the UK.
- Potential **barriers** to accessing **heath** care providers for South Asian men.
- Awareness of prostate related issues in the South Asian community.
- **Techniques** to bridge the frequent **communication** gap, reducing reliance on family members and improving the quality of written information for these patients.
- Factors which influence patients decision making when choosing **treatment** options for PCa.
- **Molecular** and **genetic research** to identify differences in PCa characteristics between the two groups.